Effect of Proton Pump Inhibitors on CF Exacerbations
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Gastroesophageal reflux disease (GERD) is a common problem in cystic fibrosis. It may lead to worsening lung function and more respiratory infections for a person with CF. This study will look at treating GERD with a medication, esomeprazole. This medication stops stomach acid from being made. The study will see if there is less respiratory infections and improved lung function in patients with CF when taking esomeprazole.
>= 18 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
Beth Israel Medical Center (Adult), New York, NY, 10003
Grece, Carroll Anne Phone: (212) 420-4196 Email: firstname.lastname@example.org
Columbia University, Adult Cystic Fibrosis Program (Adult), New York City, NY, 10032
Robinson, Victoria Phone: (212) 305-0686 Email: email@example.com